Slide 1Structural and functional outcomes in animal models of stroke: What do they measure? Malcolm Macleod University of Edinburgh Slide 2 The problem … The failure of…

Slide 1 Outline General endpoint considerations Surrogate endpoints Composite endpoints and recurrent events Safety outcomes (adverse events) Slide 2 Outline Some background…

Slide 1 What is Screening? Hui Jin Department of Epidemiology and Health Statistics School of Public Health Southeast University Slide 2 SCREENING: DEFINITION “The PRESUMPTIVE…

Slide 1 Thomas B. Newman, MD, MPH Andi Marmor, MD, MSEd October 21, 2010 Slide 2  What are screening tests supposed to do?  Definition and spectrum of screening …

Making therapeutic decisions with ongoing drug shortages Dr. Roland Halil, BSc(Hon), BScPharm, ACPR, PharmD Pharmacist, Bruyere Academic Family Health Team Assistant Professor,…

Pragmatic Randomised Trials David Torgerson Director, York Trials Unit [email protected] www.rcts.org Placebo trials These are usually seen as the âgold-standardâ method…

Statistical Issues in Clinical Studies Using Laboratory Endpoints Elizabeth S. Garrett, PhD Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University ACOSOG June…

The Future of Information Security Awareness Kelley Archer: Facilitator - Director Information Security, AIMIA Inc. Aaron Cohen: Managing Partner, MAD Security Ira Winkler:…

Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK UKPDS - Definitions Microalbuminuria (MAU) > 50 mg/L Clinical Proteinuria (CP) >300 mg/L…

Comparative Effectiveness Research: Background, Priorities, Methods * Sean Tunis MD, MSc July 10, 2009 http://www.cbo.gov/ftpdocs/89xx/doc8972/02-15-GeogHealth.pdf Quality…